- Home
- TARA vs MCRB Comparison
TARA vs MCRB Comparison
Compare TARA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- MCRB
- Stock Information
- Founded
- TARA N/A
- MCRB 2010
- Country
- TARA United States
- MCRB United States
- Employees
- TARA N/A
- MCRB N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- TARA Health Care
- MCRB Health Care
- Exchange
- TARA Nasdaq
- MCRB Nasdaq
- Market Cap
- TARA 118.1M
- MCRB 125.7M
- IPO Year
- TARA N/A
- MCRB 2015
- Fundamental
- Price
- TARA $3.03
- MCRB $16.69
- Analyst Decision
- TARA Strong Buy
- MCRB Hold
- Analyst Count
- TARA 7
- MCRB 4
- Target Price
- TARA $20.67
- MCRB $73.67
- AVG Volume (30 Days)
- TARA 214.2K
- MCRB 133.0K
- Earning Date
- TARA 08-11-2025
- MCRB 08-06-2025
- Dividend Yield
- TARA N/A
- MCRB N/A
- EPS Growth
- TARA N/A
- MCRB N/A
- EPS
- TARA N/A
- MCRB 10.22
- Revenue
- TARA N/A
- MCRB N/A
- Revenue This Year
- TARA N/A
- MCRB N/A
- Revenue Next Year
- TARA N/A
- MCRB N/A
- P/E Ratio
- TARA N/A
- MCRB $1.70
- Revenue Growth
- TARA N/A
- MCRB N/A
- 52 Week Low
- TARA $1.60
- MCRB $6.53
- 52 Week High
- TARA $10.48
- MCRB $26.40
- Technical
- Relative Strength Index (RSI)
- TARA 44.29
- MCRB 64.72
- Support Level
- TARA $3.06
- MCRB $14.06
- Resistance Level
- TARA $3.33
- MCRB $17.52
- Average True Range (ATR)
- TARA 0.17
- MCRB 1.38
- MACD
- TARA -0.01
- MCRB 0.13
- Stochastic Oscillator
- TARA 4.65
- MCRB 84.54
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.